Repair-oriented peptides and immune-modulation stacks.

Healing and recovery compounds are research peptides and small molecules studied for their effects on tissue repair, angiogenesis, mucosal stability, and recovery-related signaling pathways in preclinical research models. The Nexus catalog includes 12 compounds in this category — examples: BPC 157, TB500 (Thymosin B4 Acetate), TB500 (FRAG), BPC 2mg + TB 2mg, BPC 5mg + TB 5mg — supplied for in-vitro research use only, with COA status surfaced per product and pending certificates labeled. Healing and recovery research products include repair-oriented peptides, thymosin-family compounds, KPV, LL-37, and combination stacks built around tissue, barrier, and immune-modulation research. Nexus separates this category because buyers often need to compare standalone compounds with stack-style formats. This category is intentionally organized around research workflow rather than claims. Product pages surface variant size, COA context, and related product links so researchers can distinguish BPC, TB500, KPV, thymosin, and blend records.

Researchers in this category often examine peptide identity, blend composition, and pathway-adjacent comparison. Standalone BPC-157 and TB500 records support component-level review, while blend pages make it easier to evaluate catalog formats that combine multiple materials. Because recovery-category language can easily drift into medical claims, Nexus keeps copy factual. Category content focuses on compound families, stack composition, lab verification, and research-use boundaries.

Nexus uses batch-first product presentation with COA links, HPLC verification context, and clear research-use language. Combination products are linked to component pages when possible so buyers can inspect related records before selecting a blend.

Compounds in this category are studied in preclinical research models examining tissue-repair signaling, angiogenesis pathways, gastrointestinal mucosal stability, immune modulation, and connective-tissue research models. Common research applications include BPC-157 research on nitric oxide pathway interaction, VEGF/EGF modulation, and FAK-paxillin signaling; TB-500 research on actin sequestration and tissue migration models; KPV research on inflammatory pathway research; LL-37 research on antimicrobial and innate-immunity research; thymosin alpha-1 research on immune-modulation research models; and combination research using pre-formulated multi-peptide blends.

The 12 compounds span gastric pentadecapeptides (BPC-157 standalone and four blend formats), thymosin beta-4 family (TB-500 standalone and TB-500 fragment), thymosin alpha-1 (thymic immune-modulating peptide), KPV (alpha-MSH-derived tripeptide), LL-37 (cathelicidin antimicrobial peptide), and ACE-031 (activin receptor IIB-Fc fusion protein — structurally different from the rest of the category, requires SDS-PAGE characterization). Blend formats combine 2-4 of these peptides at varied size ratios.

The canonical research-stack pairing in this category is BPC-157 + TB-500, available standalone or pre-formulated at 2mg+2mg, 5mg+5mg, and 10mg+10mg. Tri-peptide research blends extend this with GHK-Cu (cross-category from cosmetic peptides) at BPC+GHK-Cu+TB-500 ratios; the quad blend adds KPV.

BPC-157 and TB-500 are mid-size peptides (1.4 kDa and 4.9 kDa) characterized by HPLC + ESI-MS. ACE-031 is a fusion protein requiring SDS-PAGE and Western blot in addition to mass spectrometry. Blend products receive per-component HPLC purity and per-component MS identity confirmation.